Screener
McKesson MCK North American Pharmaceutical — Receivables, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.
The source filing: McKesson’s 10-K, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal year
- FY2026
- Accession
- 0000927653-26-000069
In fiscal 2026 and 2025, the North American Pharmaceutical segment’s sales to one of the Company’s equity method investees totaled $1.6 billion and $1.1 billion, respectively. Trade receivables related to transactions from this investee were $443 million and $313 million as of March 31, 2026 and March 31, 2025, respectively.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is McKesson's north american pharmaceutical — receivables, net?
- McKesson (MCK) reported north american pharmaceutical — receivables, net of $443M in Q1 2026.
- What does north american pharmaceutical — receivables, net mean?
- This metric represents the net amount of trade receivables owed to the North American Pharmaceutical segment by its customers, including retail pharmacies, hospitals, and healthcare providers, after accounting for allowances for doubtful accounts. It reflects the credit extended to customers for pharmaceutical product distribution and serves as a key indicator of the segment's working capital efficiency and credit risk management. The balance is adjusted for estimated credit losses and write-offs to reflect the net realizable value of outstanding invoices.
Ask your AI about McKesson's north american pharmaceutical — receivables, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude